Opinion &amp; analysis

The Intersection Between Tech and Pharma Special Report (Part 2. Apple)

$3,000.00

In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

January 14, 2016

OTC Distribution in Europe – The New Global Agenda

$2,845.00

This comprehensive study identifies key factors driving change in the channels through which non-prescription/OTC medicines are distributed in Europe (18 main EU markets, plus Norway and Switzerland) and highlights the challenges facing suppliers in an ever-changing market.

January 18, 2016

The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

$3,000.00

The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

January 22, 2016

Wearables are Transforming R&D and Care Delivery

$2,995.00

Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.

June 6, 2016

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 1

$500.00

Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.

November 22, 2016

Data in Healthcare: Underpinning the Shift to Value

$2,995.00

Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.

November 23, 2016

Mail Order and Internet Pharmacy in Europe

$740.00

This 17-country study finds that continued growth of mobile technologies and e-commerce,combined with a more stable regulatory environment, are driving changes in the European mail order and Internet pharmacy market.

January 18, 2017

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 2

$500.00

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

March 16, 2017

Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 1

$400.00

The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes.

March 31, 2017

Pharma Intelligence Report Store Article Collection Digital Patient Management

The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.

April 25, 2017

Transforming Pharmaceutical R&D with Data

$2,995.00

Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%

May 2, 2017

Pharma Intelligence Report Store Article: Collection Cybersecurity

$300.00

Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.

May 19, 2017

Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 2

$300.00

Funding is taking a long time to come through for the UK NHS’s digital health care transformation, but as the national provider’s head of technology strategy, Dr Paul Rice says, “We can’t afford to remain non-digital.”

July 21, 2017

Telehealth, Wearables and Apps – Report 1

$400.00

> Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps
> Telehealth Reforms Praised At Senate Hearing
> Philips’ Survey Highlights Gaps In Perceptions Of Health Care
> Game On For Akili’s Cognitive Control Tech

December 1, 2017

Telehealth, Wearables and Apps – Report 2

$400.00

> Behind The Scenes Of Digital Health: Medtech Players And Partners
> Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care
> New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
> Siemens Healthineers To Launch Digital ‘One-Stop-Shop’

December 1, 2017

Telehealth, Wearables and Apps – Report 3

$300.00

> Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym
> Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s
> Interview: Philips Plugs Into Patient Connectivity

December 1, 2017

GSK Woes Raise Big Pharma R&D Question

Should big pharma still do in-house discovery and early development? Maybe not; GSK’s unsuccessful efforts to boost productivity suggest it’s impossible for big pharma to re-create biotech-like innovation internally. Learn why big pharma should stick to late-stage development and how it can maintain its competitive advantage.

December 4, 2017

Behind The Scenes Of Digital Health: Medtech Players And Partners

The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.

Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s

Biogen’s chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer’s Disease. Biogen CMO Alfred Sandrock has told a London neuroscience forum that constraints impeding CNS drug development include the fact diagnosis needs to be done earlier but that barrier could be mitigated in future by digital health solutions such iPhones used as “early warning” diagnostics, notably in Alzheimer’s Disease.

Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps

Victoria Hordern and Amy Merrick discuss initiatives in the EU to help app developers navigate the unclear rules on mobile health and explain why engaging patients during product development is key.

Game On For Akili’s Cognitive Control Tech

A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD).

Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care

Connected care technologies play an important role in disease prevention, but are still not used as widely as they should be. Philips’ second Future Health Index study surveyed 33,000 participants in 19 countries to compare perceptions and experiences of healthcare users across three areas – access to care, integration of health systems and adoption of connected care technologies.

Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym

RB’s spending on the WebMD-hosted Cold & Flu Tracker app generated an ROI three times greater than traditional digital marketing, says marketing executive Emma Howe. Similar campaigns are gaining momentum, with WebMD and Walgreens launching “Relief Advisor.”

Technology Gap Separates OTC Drug Firms From SelfCare Sales Growth

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

Telehealth Reforms Praised At Senate Hearing

Insurers and a neurologist testifying at a May 16 Senate Finance Committee hearing on the CHRONIC Care Act praised the bill’s telehealth provisions. Committee Chairman Orrin Hatch, R-Utah, says he plans to mark up the bill, which has been under development for two years, this week.

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

Access this exclusive In Vivo interview with Tom McGuinness, President and CEO, Imaging at GE Healthcare. He reveals GE’s secret to success in speed-to-market product launches, and explains how GE is using data analytics and software innovations to reach patients, faster.

February 21, 2018

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

Biopharma industry veteran Tadataka “Tachi” Yamada sits down with In Vivo for an exclusive interview that draws on his years of experience in many roles across the R&D ecosystem to explore the state of today’s biopharma R&D enterprise.

April 9, 2018

CEO-To-Worker Pay Ratios Averaged 150-1 At Six Top Medtech Companies In 2017

CEOs earned 32- to 215- times that of the median worker at six device companies. Find out which CEO earned $10.8 billion–215 times the median salary–and see how company revenues compare to the CEO/worker pay ratio. The average ratio for the six firms is 150-1: Discover how this compares to other public companies across industries.

April 9, 2018

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

What’s the ultimate task of an R&D organization? Industry veteran Tadataka Yamada shares his insights, offering a big-picture take on the state of the pharma R&D enterprise. Discover which areas most excite–and concern–him, and learn why “de-risking” the pipeline is harder than ever.

April 9, 2018

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

AHPA called on FDA to regulate kratom as an NDI to avoid a patchwork of state regulations. Kratom, used to manage opioid withdrawal, garnered unwelcome scrutiny after being linked to a salmonella outbreak. Will the FDA treat it like any other dietary ingredient? Find out what may lie ahead for this herbal extract.

April 30, 2018

GSK’s Head Of Artificial Intelligence Unveils R&D Goals

In this interview, John Baldoni describes GlaxoSmithKline’s artificial intelligence efforts. Baldoni, who leads GSK’s AI initiative, discusses the company’s machine-driven discovery and development methods and how they can cut time and costs. Gain insights into the AI team’s timeline and what it has accomplished already. Discover who GSK’s AI partners are–and why such deals are “tricky.”

April 30, 2018

US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?

The U.S. FDA’s reorganization of its Office of New Drugs (OND) faces leadership challenges, thanks to recent departures. How will the FDA staff these new divisions? Learn more about the departures, gain insights into the agency’s options, and explore the implications for the industry.

May 1, 2018

Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

Sanofi and Regeneron made an offer: They would drop the cost of their PCSK9 inhibitor Praluent (alirocumab) for improved access. Express Scripts took them up on it. Learn whether this deal will affect the high rejection rate for PCSK9 drugs. Find out whether this deal is a one-off or the start of a trend.

May 1, 2018

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

Hawaii’s ban on the sale of sunscreens containing octinoxate and oxybenzone is expected to go into effect in 2021. It’s intended to protect marine ecosystems–in particular, coral. Opponents of the law included the Consumer Healthcare Product Association and the Hawaii Medical Association. Find out how manufacturers will adjust, and gain insights into the U.S. FDA’s perspective on regulating certain sunscreen ingredients.

May 2, 2018

Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says

Global regulators are looking to converge–or at least align–various requirements, and the US FDA is no exception. Officials have strongly suggested that the agency will replace its Quality System Regulation with ISO 13485. It won’t be simple. Discover the implications for device makers, and find out what’s involved in making this dramatic change.

May 4, 2018

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

A federal class-action suit alleges Rodan + Fields hid prostaglandin risks from consumers using Lash Boost. The lawsuit will likely draw attention to prostaglandin analogs in eyelash enhancers. Find out what this means for the lash-enhancement market in terms of litigation and regulatory activity.

May 7, 2018

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments

Novartis AG’s involvement–however tangential–in the Donald Trump/Michael Cohen/Stormy Daniels scandal is just the latest incident to tarnish the pharmaceutical industry’s public image. Explore how negative public perception could accelerate the move to price controls–and why it’s an industry-wide problem.

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

Will drug rebates become illegal? U.S. FDA Commissioner Scott Gottlieb has suggested as much, and PBMs, among others, are paying close attention. Explore the implications–especially for PBMs–and find out why this is historically such a hot-button policy issue.

US FDA Commissioner: Agency Will Propose New Rule That Blends Quality System Regulation, ISO 13485

The US FDA plans to “harmonize domestic and international requirements, and modernize the regulation” through a new rule that will blend its Quality System Regulation (QSR) with ISO 13485. Will FDA will swap out the QSR with ISO 13485? Probably not. Find out what it will likely do instead–and when it will do it.

Pfizer’s Reference Point on Trial Innovation : Ask the Patient

In this interview with Pfizer’s head of clinical innovation, Craig Lipset, learn why clinical trial innovation requires a patient-centered approach and how Pfizer is making this happen. Learn why patient-centricity matters. Explore how the digital revolution is reshaping patient engagement, data collection and the shape of clinical trials.

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

The Trump Administration’s “Blueprint to Lower Prices and Reduce Out-of-Pocket Costs” includes dramatic changes to protected classes, rebates and PBM reimbursement. Discover why the blueprint has industry leaders worried. Explore the implications for biopharmas and PBMs in particular and the healthcare industry in general.

May 11, 2018

Takeda/Shire Merger: Five Things To Worry About

The Takeda/Shire merger will catapult the new company to the “top 10” pharma list, but greater size brings greater challenges, including manufacturing glitches and review issues. Explore the challenges each company brought to the merger and the new ones the merged faces today.

May 16, 2018

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

Estée Lauder’s CEO revealed that “a small group of employees” was responsible for intentionally altering test results behind product claims. The shocking disclosure was mitigated by the fact that the problem was discovered internally. Nevertheless, stock tumbled following the announcement–but has largely recovered. Find out how the disclosure may affect Lauder moving forward, and learn how analysts reacted

May 16, 2018

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

Big data, AI and machine learning are no longer mere buzzwords; they have transformed clinical trial data analysis. Learn how technological advances can address both the high-touch challenges posed by patient engagement and the high-tech challenge of turning unstructured data into actionable information for clinical trials

May 16, 2018